RecruitingPhase 2NCT06530576
Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
Studying Neutropenia-hyperlymphocytosis with large granular lymphocytes syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Principal Investigator
- Shuhua Yi, DoctorInstitute of Hematology & Blood Diseases Hospital, China
- Intervention
- Thalidomide and methotrexate(drug)
- Enrollment
- 48 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06530576 on ClinicalTrials.govOther trials for Neutropenia-hyperlymphocytosis with large granular lymphocytes syndrome
Additional recruiting or active studies for the same condition.
See all trials for Neutropenia-hyperlymphocytosis with large granular lymphocytes syndrome →